Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 16/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941507 | 0.85 | MEN1 (0.50) | MEN1KMT2AP2RX3HTTL3MBTL1 | |
| SCHEMBL8941674 | 0.82 | F2 (0.46) | HTT | |
| SCHEMBL21330640 | 0.81 | MEN1 (0.48) | MEN1KMT2AP2RX3HTTL3MBTL1 | |
| SCHEMBL21330627 | 0.81 | MEN1 (0.52) | MEN1KMT2AP2RX3HTT | |
| SCHEMBL11684536 | 0.81 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL10980485 | 0.81 | HTT (0.47) | MEN1KMT2AP2RX3HTTL3MBTL1 | |
| SCHEMBL958339 | 0.81 | MEN1 (0.51) | MEN1KMT2AP2RX3HTTL3MBTL1 | |
| SCHEMBL22061575 | 0.80 | F2 (0.41) | — | |
| SCHEMBL7228289 | 0.79 | KDM4E (0.47) | — | |
| SCHEMBL9771157 | 0.78 | HTT (0.47) | MEN1KMT2AP2RX3HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| CN-108069974-B | Selective Bruton tyrosine kinase inhibitor and application thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2019-12-10 | — | — | CN | disclosed |
| EP-3543239-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | BTK, BMX, KCNK10 | MEN1 2111/4885KMT2A 2028/4885P2RX3 947/4885 |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | BTK, SYK, LYN | MEN1 2441/4885KMT2A 1652/4885P2RX3 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.